MAM
ZYNE

Meeder Asset Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Meeder Asset Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,438
Closed -$9K – 2586
2020
Q1 		$9K Buy
+2,438
New +$11.3K ﹤0.01% 1590
2019
Q4 		– Sell
-1,266
Closed -$9K – 2459
2019
Q3 		$9K Buy
+1,266
New +$14.3K ﹤0.01% 1583

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Meeder Asset Management's ZYNE Position: Q2 2020 in Review

Meeder Asset Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 2,438 shares — an estimated $9K sold.

Meeder Asset Management first reported a position in ZYNE in Q3 2019 and held it in 2 quarters. The position peaked at $9K in Q1 2020. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Meeder Asset Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 2,438 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $9K.
  • Meeder Asset Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 2 quarters.
  • Meeder Asset Management's Zynerba Pharmaceuticals, Inc position peaked at $9K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.